← Oncology Approval Tracker

FDA DECISION ·

Truseltiq

infigratinib · QED Therapeutics

Accelerated approvalNew therapyCholangiocarcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on May 16, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement by an FDA-approved test. FDA withdrew approval on May 16, 2024.

LAMPGEN ANALYSIS

Why it matters

The accelerated action addressed previously treated FGFR2-altered biliary cancer and was later withdrawn.

What research teams should watch

Retain the FGFR2 alteration class, prior therapy and both regulatory dates for historical comparisons.

PRIMARY RECORDS

Sources